BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 11961667)

  • 21. Adenovirus-mediated transfer of inducible caspases: a novel "death switch" gene therapeutic approach to prostate cancer.
    Shariat SF; Desai S; Song W; Khan T; Zhao J; Nguyen C; Foster BA; Greenberg N; Spencer DM; Slawin KM
    Cancer Res; 2001 Mar; 61(6):2562-71. PubMed ID: 11289132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors.
    Wu L; Matherly J; Smallwood A; Adams JY; Billick E; Belldegrun A; Carey M
    Gene Ther; 2001 Sep; 8(18):1416-26. PubMed ID: 11571582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A small chimeric promoter for high prostate-specific transgene expression from adenoviral vectors.
    Kraaij R; van der Weel L; de Ridder CM; van der Korput HA; Zweistra JL; van Rijswijk AL; Bangma CH; Trapman J
    Prostate; 2007 Jun; 67(8):829-39. PubMed ID: 17394196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adenovirus-mediated interferon-beta gene transfer inhibits angiogenesis in and progression of orthotopic tumors of human prostate cancer cells in nude mice.
    Lee J; Wang A; Hu Q; Lu S; Dong Z
    Int J Oncol; 2006 Dec; 29(6):1405-12. PubMed ID: 17088978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer.
    Martiniello-Wilks R; Wang XY; Voeks DJ; Dane A; Shaw JM; Mortensen E; Both GW; Russell PJ
    J Gene Med; 2004 Dec; 6(12):1343-57. PubMed ID: 15493036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
    Zerbini LF; Wang Y; Cho JY; Libermann TA
    Cancer Res; 2003 May; 63(9):2206-15. PubMed ID: 12727841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate cancer radiosensitization in vivo with adenovirus-mediated p53 gene therapy.
    Cowen D; Salem N; Ashoori F; Meyn R; Meistrich ML; Roth JA; Pollack A
    Clin Cancer Res; 2000 Nov; 6(11):4402-8. PubMed ID: 11106260
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors.
    Djeha AH; Thomson TA; Leung H; Searle PF; Young LS; Kerr DJ; Harris PA; Mountain A; Wrighton CJ
    Mol Ther; 2001 Feb; 3(2):233-40. PubMed ID: 11237680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A cox-2 promoter-based replication-selective adenoviral vector to target the cox-2-expressing human bladder cancer cells.
    Shirakawa T; Hamada K; Zhang Z; Okada H; Tagawa M; Kamidono S; Kawabata M; Gotoh A
    Clin Cancer Res; 2004 Jul; 10(13):4342-8. PubMed ID: 15240520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate targeting: PSP94 gene promoter/enhancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model.
    Gabril MY; Onita T; Ji PG; Sakai H; Chan FL; Koropatnick J; Chin JL; Moussa M; Xuan JW
    Gene Ther; 2002 Dec; 9(23):1589-99. PubMed ID: 12424611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Purine-rich element binding protein (PUR) alpha induces endoplasmic reticulum stress response, and cell differentiation pathways in prostate cancer cells.
    Inoue T; Maeno A; Talbot C; Zeng Y; Yeater DB; Leman ES; Kulkarni P; Ogawa O; Getzenberg RH
    Prostate; 2009 Jun; 69(8):861-73. PubMed ID: 19267365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene therapy for prostate cancer by targeting poly(ADP-ribose) polymerase.
    Trofimova I; Dimtchev A; Jung M; Rosenthal D; Smulson M; Dritschilo A; Soldatenkov V
    Cancer Res; 2002 Dec; 62(23):6879-83. PubMed ID: 12460902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel targeting modality to enhance adenoviral replication by vitamin D(3) in androgen-independent human prostate cancer cells and tumors.
    Hsieh CL; Yang L; Miao L; Yeung F; Kao C; Yang H; Zhau HE; Chung LW
    Cancer Res; 2002 Jun; 62(11):3084-92. PubMed ID: 12036918
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter.
    Pramudji C; Shimura S; Ebara S; Yang G; Wang J; Ren C; Yuan Y; Tahir SA; Timme TL; Thompson TC
    Clin Cancer Res; 2001 Dec; 7(12):4272-9. PubMed ID: 11751529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory prostate cancer.
    McCarthy HO; Coulter JA; Worthington J; Robson T; Hirst DG
    J Gene Med; 2007 Jun; 9(6):511-20. PubMed ID: 17471586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate-specific targeting using PSA promoter-based lentiviral vectors.
    Yu D; Chen D; Chiu C; Razmazma B; Chow YH; Pang S
    Cancer Gene Ther; 2001 Sep; 8(9):628-35. PubMed ID: 11593331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
    Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
    J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression.
    Rubinchik S; Wang D; Yu H; Fan F; Luo M; Norris JS; Dong JY
    Mol Ther; 2001 Nov; 4(5):416-26. PubMed ID: 11708878
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus.
    Wang XY; Martiniello-Wilks R; Shaw JM; Ho T; Coulston N; Cooke-Yarborough C; Molloy PL; Cameron F; Moghaddam M; Lockett TJ; Webster LK; Smith IK; Both GW; Russell PJ
    Gene Ther; 2004 Nov; 11(21):1559-67. PubMed ID: 15343359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
    Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
    Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.